Reclast (Zoledronic Acid) in Children Under 12: Off-Label Use, Evidence, and Clinical Guidance

Why Zoledronic Acid Is Used Off-Label in Young Children

Zoledronic acid suppresses osteoclast-mediated bone resorption more potently than any oral bisphosphonate, and a single annual IV infusion can achieve what daily oral alendronate requires a year to sustain. In children under 12 who cannot reliably swallow and remain upright after a tablet, IV delivery removes an important compliance barrier. The FDA has not granted a pediatric indication for Reclast, so every use in this age group is off-label and requires informed consent documentation reflecting that status. Prescribing information for Reclast confirms the adult-only labeling.

What "Off-Label" Means in Practice

Off-label use is legal and common in pediatric medicine. The American Academy of Pediatrics has noted that roughly 75% of drugs used in hospitalized children lack a pediatric label. Physicians prescribing zoledronic acid to a child under 12 are acting within standard-of-care norms for rare skeletal diseases, provided they document the clinical rationale, discuss alternatives, and obtain appropriate consent.

Conditions That Drive Prescribing

The three conditions most frequently prompting off-label zoledronic acid in children under 12 are osteogenesis imperfecta, glucocorticoid-induced osteoporosis (GIOP), and osteoporosis secondary to neuromuscular disease (e.g., Duchenne muscular dystrophy, cerebral palsy). Each shares the common denominator of high fracture burden combined with poor tolerance of daily oral regimens. A 2012 Cochrane review of bisphosphonates for OI found that IV pamidronate reduced vertebral fracture risk and improved lumbar spine BMD, establishing the proof-of-concept that zoledronic acid, the more potent nitrogen-containing bisphosphonate, then extended.

Osteogenesis Imperfecta: The Primary Evidence Base

Osteogenesis imperfecta is the condition for which pediatric zoledronic acid data are richest. Children with moderate-to-severe OI (types III and IV) can sustain dozens of fractures before age 10, and lumbar spine bone mineral density Z-scores at diagnosis typically fall below minus 2.0. Multiple prospective studies now show that annual or semi-annual zoledronic acid infusions at 0.025 to 0.05 mg/kg (capped at 4 mg) raise lumbar spine BMD Z-scores by 0.5 to 1.5 standard deviations over one to three years. Vuorimies et al. (2011, JCEM) reported a mean lumbar spine BMD increase of 24% after two annual zoledronic acid infusions in 25 children with OI, with no serious adverse events beyond expected acute-phase reactions.

Head-to-Head Data Against Pamidronate

The ZIPP trial (Glorieux et al., 2019) directly compared zoledronic acid with pamidronate in 77 children aged 1 to 17 with OI types I, III, and IV. Published in the Journal of Bone and Mineral Research, ZIPP showed that zoledronic acid at 0.05 mg/kg (max 4 mg) twice yearly produced non-inferior lumbar spine areal BMD gains versus pamidronate at standard dosing over two years (mean change in BMD Z-score: +0.74 vs. +0.67, P for non-inferiority <0.001). Fracture rates were similar between arms. The authors concluded that zoledronic acid's twice-yearly dosing represents a clinically meaningful reduction in infusion burden compared with pamidronate's three-times-yearly schedule.

Fracture Outcomes Specifically in Children Under 5

Data are thinner for the youngest patients. A retrospective series by Bala et al. (2018) reviewed 32 children aged 6 months to 5 years with OI types III and IV who received zoledronic acid. Published in Bone, the series found a 38% reduction in annualized long-bone fracture rate over 24 months, although the lack of a concurrent control group limits causal inference. Acute-phase reactions occurred in 68% of patients after their first infusion and fell to 12% by the third infusion.

Dosing Protocols Used in OI Trials

No single consensus protocol exists for children under 12. The most commonly cited schema across published trials is:

• Age <3 years: 0.025 mg/kg per infusion, twice yearly
• Age 3 to 11 years: 0.05 mg/kg per infusion (max 4 mg), once or twice yearly depending on OI severity
• Infusion duration: minimum 15 minutes for doses <2 mg; 30 to 45 minutes for doses 2 to 4 mg

These thresholds are derived from pharmacokinetic modeling studies, including Letocha et al. (2004), which established that children clear zoledronate more rapidly per kilogram than adults, supporting weight-based rather than flat dosing.

Glucocorticoid-Induced Osteoporosis in Young Children

Children receiving long-term glucocorticoids for conditions such as nephrotic syndrome, inflammatory bowel disease, or systemic lupus erythematosus are at high risk for vertebral fractures. Prednisone at doses exceeding 0.1 mg/kg/day for more than three months suppresses osteoblast activity and accelerates bone resorption, dropping lumbar spine BMD Z-scores by 0.3 to 0.8 SD per year without intervention. The 2017 ACR guideline on glucocorticoid-induced osteoporosis recommends bisphosphonate therapy in children aged 5 and older who have a prior fracture or a BMD Z-score below minus 2.0 and are expected to remain on glucocorticoids for more than three months.

Why Zoledronic Acid Is Chosen Over Oral Agents

Oral alendronate and risedronate carry pediatric data but require weekly or daily administration with strict fasting and positioning requirements. In children with gastrointestinal disease (common in IBD and nephrotic syndrome), GI tolerability is already compromised. Zoledronic acid's annual infusion sidesteps these barriers. A prospective study by Rudge et al. (2005) in 18 children with steroid-dependent juvenile idiopathic arthritis showed that a single 0.05 mg/kg zoledronic acid infusion increased lumbar spine BMD by 9.2% at 12 months, a gain roughly double that seen with weekly oral alendronate in comparable populations.

Monitoring Schedule for GIOP

Before the first infusion, clinicians should confirm:

1. 25-OH vitamin D above 20 ng/mL (supplement to 30 to 50 ng/mL if possible)
2. Serum calcium within normal pediatric reference range
3. Estimated GFR above 35 mL/min/1.73m² using the Schwartz formula
4. Baseline lumbar spine and total hip (or total body less head) DXA with Z-scores

Post-infusion labs at 24 to 48 hours should include serum calcium and phosphate. Symptomatic hypocalcemia after the first infusion is uncommon when vitamin D has been repleted but can be serious; IV calcium gluconate should be available during and for two hours after infusion in any child with baseline 25-OH vitamin D below 15 ng/mL. The Endocrine Society's 2010 clinical practice guideline on vitamin D deficiency provides the repletion targets that inform pre-infusion optimization.

Neuromuscular Disease and Secondary Osteoporosis

Children with Duchenne muscular dystrophy (DMD) and cerebral palsy (CP) represent another sizable off-label population. Both conditions combine disuse osteoporosis with glucocorticoid exposure (particularly in DMD). A 2019 study in the Journal of Pediatric Orthopaedics evaluated 41 boys aged 4 to 12 with DMD who received annual zoledronic acid at 0.05 mg/kg. Lumbar spine BMD Z-scores improved by a mean of +0.62 SD at 12 months, and the vertebral fracture rate dropped from 0.87 per patient-year at baseline to 0.33 per patient-year during the study period.

Cerebral Palsy Specifics

Vertebral and femoral fractures in non-ambulatory children with CP often occur with minimal or no identifiable trauma. Henderson et al. (2002) showed that non-ambulatory children with CP had distal femur BMD Z-scores averaging minus 3.7, a deficit large enough to classify as severe osteoporosis by adult equivalents. Zoledronic acid case series in this population report BMD gains of 8 to 15% over 12 months, though prospective controlled trials are lacking.

Safety Profile in Children Under 12

Acute-Phase Reaction

The most common adverse effect after the first infusion is an acute-phase reaction: fever (38 to 40°C), myalgia, arthralgia, and headache appearing within 24 to 48 hours and resolving within 72 hours without intervention. Rates across pediatric studies range from 40% to 70% after the first infusion. Pre-medication with acetaminophen 15 mg/kg at the time of infusion and every 6 hours for 24 hours reduces severity but does not reliably prevent the reaction. Kinane et al. (2014) reported that only 8% of children experienced a second acute-phase reaction after the first infusion had already caused one, confirming the diminishing recurrence pattern seen in adult data.

Hypocalcemia

Symptomatic hypocalcemia is the most clinically serious short-term risk. Zoledronic acid suppresses bone resorption sharply, cutting off calcium flux from bone into the bloodstream. In children with unrecognized vitamin D deficiency, the nadir serum calcium can drop below 1.9 mmol/L within 24 to 48 hours. Gafni et al. (2012) described seven cases of symptomatic hypocalcemia in children with OI following IV bisphosphonate, all of whom had 25-OH vitamin D below 15 ng/mL at infusion. The authors recommended a minimum pre-infusion 25-OH vitamin D of 20 ng/mL and oral calcium supplementation of 500 to 1000 mg/day for 10 days post-infusion.

Renal Function

Zoledronic acid is renally cleared with a terminal half-life of approximately 167 hours in adults. The Reclast FDA prescribing label contraindicates use when creatinine clearance falls below 35 mL/min. In children, GFR estimation using the Schwartz formula (eGFR = 0.413 x height in cm / serum creatinine) is standard before each cycle. Children with nephrotic syndrome or single kidneys warrant particular scrutiny before every infusion.

Jaw Osteonecrosis and Atypical Femoral Fracture

Osteonecrosis of the jaw (ONJ) and atypical subtrochanteric femoral fractures are rare but recognized adult bisphosphonate complications. Pediatric case reports of ONJ exist but are almost exclusively associated with dental extractions during active bisphosphonate therapy. A 2016 systematic review in Osteoporosis International identified fewer than 15 pediatric ONJ cases in the published literature through 2015, all in patients on prolonged IV therapy. Routine dental screening before initiating therapy and avoidance of invasive dental procedures during treatment are standard precautions. Atypical femoral fracture has been reported in adolescents after extended bisphosphonate courses but not yet documented in children under 12 with zoledronic acid specifically.

Pre-Treatment Workup and Contraindications

Before the first infusion of zoledronic acid in a child under 12, a structured workup reduces preventable harm.

Required Labs

• Complete metabolic panel including calcium, phosphate, magnesium, and creatinine
• 25-OH vitamin D
• PTH (to exclude hypoparathyroidism or secondary hyperparathyroidism)
• Urine calcium-to-creatinine ratio (to screen for hypercalciuria before supplementing calcium)
• Alkaline phosphatase and bone-specific alkaline phosphatase if available

Imaging

• DXA of lumbar spine (L1, L4) and total body less head
• Lateral spine radiograph or VFA (vertebral fracture assessment) to document baseline vertebral morphology

Absolute Contraindications

• Hypocalcemia (must be corrected before infusion)
• Active pregnancy (not applicable under 12 but applicable in adolescents)
• Hypersensitivity to any bisphosphonate
• Severe renal impairment (eGFR <35 mL/min/1.73m²)

The Pediatric Endocrine Society's position statement on bisphosphonate use in children echoes these contraindications and recommends that infusions occur at centers with pediatric expertise and IV calcium access.

Dosing and Administration Specifics

Weight-Based Calculation

The most widely replicated dosing formula in trials enrolling children under 12 is 0.05 mg/kg per dose (maximum 4 mg), given as a slow IV infusion in 100 to 250 mL normal saline over 30 to 45 minutes. For children under age 3 or those weighing under 15 kg, 0.025 mg/kg per dose is used to reduce the intensity of acute-phase reactions while preserving BMD benefit. Barros et al. (2012) compared 0.025 mg/kg and 0.05 mg/kg in 40 children under 6 with OI and found equivalent BMD gains at 12 months, suggesting the lower dose is sufficient in the youngest patients.

Frequency

Annual infusions are standard for mild OI (type I) and GIOP in children with BMD Z-scores between minus 1.5 and minus 2.5. Semi-annual infusions (every 6 months) are used in children with severe OI (types III and IV), multiple vertebral fractures, or BMD Z-scores below minus 3.0. After 2 to 3 years of treatment and stabilization of BMD Z-scores, some centers reassess the need for continuation at annual intervals. Ward et al. (2007) showed that BMD gains plateau after 3 years of IV bisphosphonate in children with OI, supporting a re-evaluation rather than indefinite continuation.

Pre-Medication Protocol

A standard pre-medication protocol at most centers includes:

• Acetaminophen 15 mg/kg (max 1 g) 30 minutes before infusion
• Oral hydration: 1 to 2 mL/kg/hour for 2 hours pre-infusion
• Normal saline IV flush before and after zoledronate

Some centers add ibuprofen 10 mg/kg every 6 hours for 24 hours post-infusion in children old enough to receive NSAIDs. Corticosteroid pre-medication is not routinely recommended and has not shown benefit in published pediatric series.

Monitoring After Each Infusion Cycle

Serum calcium should be rechecked at 24 to 48 hours after each infusion in any child with a baseline 25-OH vitamin D below 25 ng/mL or a history of hypocalcemia with prior bisphosphonate. For children with adequate baseline vitamin D, clinical monitoring for hypocalcemia symptoms (perioral tingling, muscle cramps, positive Chvostek sign) during the 48 hours post-infusion is sufficient. DXA should be repeated every 12 to 24 months. The International Society for Clinical Densitometry (ISCD) 2019 pediatric positions specify that lumbar spine DXA with Z-scores (not T-scores) is the standard assessment tool for children, and that a clinically meaningful response to therapy is defined as a Z-score change of at least +0.3 SD per year.

Regulatory and Consent Considerations

Zoledronic acid carries no pediatric exclusivity studies and no FDA pediatric labeling for patients under 18. Prescribers should document that:

1. An FDA-approved alternative (e.g., oral alendronate with its limited pediatric data) was considered and found less appropriate for this specific patient.
2. The family received a clear explanation that Reclast is not FDA-approved for children.
3. The specific off-label indication, expected benefits, and known risks were discussed.

The FDA's Pediatric Research Equity Act (PREA) did not compel bisphosphonate manufacturers to conduct pediatric studies because osteoporosis treatments for adults are not subject to PREA in the absence of a pediatric disease claim. The FDA's summary of PREA requirements clarifies this exemption. Consequently, the off-label evidence base in children under 12 will remain composed of investigator-initiated trials and registries rather than manufacturer-sponsored programs for the foreseeable future.

What the Evidence Does Not Yet Tell Us

Five-year and longer BMD and fracture data in children under 12 treated with zoledronic acid are unavailable from randomized controlled trials. The theoretical concern about suppressing bone modeling during a period of rapid skeletal growth has not materialized as a detectable signal in 2 to 3 year trial follow-up, but longer-term surveillance studies are needed. The effect of zoledronic acid on growth plate function is an area of ongoing investigation; Rauch et al. (2007) showed no adverse effect of IV pamidronate on tibial length or growth velocity in 112 OI children followed for 3 years, offering indirect reassurance for structurally similar nitrogen-containing bisphosphonates including zoledronate.